Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06610799

Study of IBI363 in Patients with Advanced First-line Gastric Cancer

Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of IBI363 in Combination with Oxaliplatin and Capecitabine (XELOX) in First-line Treatment of Unresectable Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Sponsor: Xiangdong Cheng

Conditions IBI363 + Chemotherapy

Interventions IBI363

Updated 2 times since 2024 Last updated: Nov 18, 2024 Started: Oct 15, 2024 Primary completion: Jun 30, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06610799, this PHASE1 trial focuses on IBI363 + Chemotherapy and remains actively recruiting participants. Sponsored by Xiangdong Cheng, it has been updated 2 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Dec 2024 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xiangdong Cheng

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China